Revised. Amendments from Version 1
==================================

We have expanded the limitations section of the discussion to highlight points made by the reviewers: in particular that the available data are scanty and hence may not be generalisable across sub-Saharan Africa, and that some risk factors for ESBL-E carriage (in particular the role of livestock and HIV infection) are not well assessed in the identified studies. Their role in driving colonisation, therefore, remains unclear.

Introduction
============

Extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) are a significant threat to human health, and have been identified by the World Health Organisation as pathogens of critical importance ^[@ref-1]^. In sub-Saharan Africa (sSA), it is increasingly clear that a significant proportion of invasive Enterobacteriaceae infections are ESBL-E and the absence of second line antimicrobials can render infections with these pathogens locally untreatable ^[@ref-2]^. Strategies to interrupt ESBL-E transmission that can be practically deployed at scale in low resource settings are urgently needed.

Gut mucosal colonisation with Enterobacteriaceae is thought to precede invasive infection ^[@ref-3],\ [@ref-4]^, and so preventing ESBL-E colonisation is an attractive strategy for prevention of invasive disease. Data describing the basic epidemiology of ESBL-E colonisation in sSA, will help inform the design of interventions targeted at reducing colonisation. A 2016 meta-analysis of community ESBL-E colonisation prevalence among healthy individuals found only four studies from sSA with a pooled prevalence of 15% (95% CI 4--31%), and significant between-study heterogeneity ^[@ref-5]^. No studies described risk factors from Africa. We were aware of a number of studies that had been published since 2016 including a number that described ESBL-E colonisation in any population, so undertook a systematic review and meta-analysis with two aims: firstly, to describe the prevalence of ESBL-E gut mucosal colonisation in sSA; and secondly, to describe any risk factors associated with colonisation. In terms of the PRISMA (preferred reporting items for systematic reviews and meta analyses) PICOS (participants, interventions, comparisons, outcomes and study design) approach, our questions can be framed as: what is the prevalence of ESBL-E gut mucosal colonisation (the outcome) and risk factors for colonisation (comparisons) in any population in sSA (the population) as measured in prospective cross-sectional or cohort studies (study design).

Methods
=======

Inclusion criteria were any prospective cross-sectional or cohort study that had screened for gut mucosal colonisation of ESBL-E in any population in sSA for which it was possible to extract a numerator and denominator to calculate an ESBL-E colonisation prevalence. Exclusion criteria were studies in which the sampled population was not clearly defined in a reproducible way (i.e. laboratory-based studies), or if the laboratory techniques aimed to isolate only a particular organism or type of organism (e.g. Enteropathogenic *E. coli).* PubMed and Scopus were searched in all fields using the search terms given in [Table 1](#T1){ref-type="table"}, on 18 December 2018. Abstracts were extracted into Endnote X7.8 (Thomson Reuters, United States) and independently reviewed against the inclusion criteria by two authors (JL and RL), with disagreements settled by consensus.

###### Systematic review search terms.

  ---------------------------------------------------------------------------------------------------------------------------
  ((ESBL) OR Extended-spectrum beta-lactamase)) AND (((Angola OR Benin OR Botswana OR Burkina Faso OR Burundi OR\
  Cameroon OR Cape Verde OR Central African Republic OR Chad OR Comoros OR Republic of the Congo OR Congo Brazzaville\
  OR Democratic republic of the Congo OR Cote d'Ivoire OR Djibouti OR Equatorial Guinea OR Eritrea OR Ethiopia OR Gabon OR\
  The Gambia OR Ghana OR Guinea OR Guinea-Bissau OR Kenya OR Lesotho OR Liberia OR Madagascar OR Malawi OR Mali OR\
  Mauritania OR Mauritius OR Mozambique OR Namibia OR Niger OR Nigeria OR Reunion OR Rwanda OR Sao Tome and Principe\
  OR Senegal OR Seychelles OR Sierra Leone OR Somalia OR South Africa OR Sudan OR Swaziland OR Eswatini OR Tanzania OR\
  Togo OR Uganda OR Western Sahara OR Zambia OR Zimbabwe) OR Africa))

  ---------------------------------------------------------------------------------------------------------------------------

Full-text review of included studies was then undertaken, with studies assessed against the same inclusion criteria, again with disagreements settled by consensus. Data were then extracted into a Microsoft Excel for Mac v16.27 spreadsheet (Microsoft, United States): study title and authors, year of publication, dates of sample collection, inclusion criteria, median age or participants, details of microbiologic testing procedures, number of participants and number of participants from whom ESBL-E were isolated, and any risk factors for ESBL-E that were assessed and/or found to be associated with ESBL-E colonisation. Two authors extracted data independently (RL and JL) and any inconsistencies corrected by re-review of the original paper. For cohort studies only the baseline prevalence was included. Prevalence was presented as forest plots with exact binomial confidence intervals. Age group (neonate, child, adult, as per study definition) and location of sampling (community, outpatient \[including health centre attendees\], on hospital admission, \[defined as a hospital inpatient for \< 24hr\] hospitalised, \[defined as a hospital inpatient for \> 24hr\]) were selected as *a priori* subgroups that we hypothesised may explain heterogeneity in ESBL-E prevalence, and analyses were stratified by these subgroups. Studies were additionally classified as being carried out in a *special population* if they were carried out in a subpopulation of a subgroup (for example, pregnant women in the community). Effect size of risk factors for ESBL-E colonisation were presented as odds ratios; if odds ratios were not provided by the original studies then they were calculated, with 0.5 added to zero cells. Pooled random effect summary estimates of prevalence, where calculated, were generated using the *metaprop* package in R using the inverse variance method with a logit transformation. All analysis was undertaken using R v3.5.1 (R Foundation for Statistical Computing, Vienna, Austria).

Risk of bias of included studies was assessed with a modified Critical Appraisal Skills Programme (CASP) checklist, designed to fit our research question (full tool available as *extended data*). The risk of bias assessment was performed by JL and RL, and any disagreements were resolved by consensus.

The protocol of this review was published on PROSPERO (PROSPERO ID [CRD42019123559](https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=123559)) and the review was undertaken as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PRISMA checklist available *Reporting guidelines*).

Results
=======

Of 2975 identified unique studies, 32 were included in this review ^[@ref-6]--\ [@ref-37]^ ( [Figure 1](#f1){ref-type="fig"}), from 19 countries in sSA ( [Table 2](#T2){ref-type="table"}). Studies from three countries -- Tanzania (n=7), Madagascar (n=4) and Cameroon (n=4) - together made up 15/32 (47%) of the available studies. In total, 8619 participants were included and for 7232/8619 (84%) it was possible to disaggregate the participants into age groups: 4313/7232 (60%) were adults, 2470/7232 (34%) children and 449/7232 (6%) neonates. 2302/8619 (27%) of included participants were community members, 1729/8619 (20%) were outpatients, 2836/8619 (33%) were sampled on admission to hospital, and 1534/8619 (18%) were inpatients. 6/32 studies were cohort studies; all of these studies followed patients up whilst hospitalised only. Many studies were carried out in special populations, including the majority of community studies: 9/12 community studies were in special populations, as well as 3/7 outpatient studies, 3/8 studies of participants on hospital admission and 2/7 inpatient studies. It was not possible to classify patients from two studies into our predefined categories: one sampled staff and children of an orphanage, and the other hospital workers and their families. These studies were excluded from the pooled analyses. Details of the microbiological testing procedures are shown in [Table 3](#T3){ref-type="table"}.

![Flow chart of included studies.](wellcomeopenres-4-17211-g0000){#f1}

###### Details of included studies.

CAR = Central African Republic; ART = antiretroviral therapy; UTI = urinary tract infection; NR = not reported. yr = year; m = months, d = days, hr = hours. \* = mean rather than media.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Year\                                  Study\     Country        Study\       Inclusion\                                         Age\       Median\                                n
                                       Pub.                                   Period                    Type         Population: details                                group      age                                    
  ------------------------------------ -------------------------------------- ---------- -------------- ------------ -------------------------------------------------- ---------- -------------------------------------- -----
  **COMMUNITY STUDIES**                                                                                                                                                                                                   

  Albrechtova 2012                     2012                                   2009       Kenya          Cross sec.   General population                                 Adults     NR                                     23

  Mshana 2016                          2016                                   2014       Tanzania       Cross sec.   General population                                 both       10yr                                   334

  Katakweba 2018                       2018                                   2011--13   Tanzania       Cross sec.   General population                                 Adults     NR                                     70

  Ruppe 2009                           2009                                   NR         Senegal        Cross sec.   Special population (remote villages)               Children   6.9yr [\*](#TFN1){ref-type="other"}    20

  Lonchel 2012                         2012                                   2009       Cameroon       Cross sec.   Special population (students)                      Adults     24.7yr [\*](#TFN1){ref-type="other"}   150

  Chereau 2015                         2015                                   2013--14   Madagascar     Cross sec.   Special population (pregnant women)                Adults     26yr [\*](#TFN1){ref-type="other"}     356

  Farra 2016                           2016                                   2013       CAR            Cross sec.   Special population (healthy controls in a\         Children   10.5m                                  134
                                                                                                                     diarrhoea study)                                                                                     

  Ribeiro 2016                         2016                                   2013       Angola         Cross sec.   Special population (no antibiotics/hospital\       Adults     NR                                     
                                                                                                                     exposure last 3 mo)                                                                                  

  Tellevik 2016                        2016                                   2010--11   Tanzania       Cross sec.   Special population: \<2yr attending health\        Children   NR                                     250
                                                                                                                     centre for vaccine                                                                                   

  Moremi 2017                          2017                                   2015       Tanzania       Cross sec.   Special population (street children)               Children   14.2yr [\*](#TFN1){ref-type="other"}   107

  Chirindze 2018                       2018                                   2016       Mozambique     Cross sec.   Special population (Students in the\               Adults     NR                                     275
                                                                                                                     community)                                                                                           

  Sanneh 2018                          2018                                   2015       The Gambia     Cross sec.   Special population (Food handlers in schools)      Adults     37yr [\*](#TFN1){ref-type="other"}     565

  **HOSPITAL OUTPATIENTS**                                                                                                                                                                                                

  Herindrainy 2011                     2011                                   2009       Madagascar     Cross sec.   Outpatients                                        Adults     NR                                     306

  Lonchel 2012                         2012                                   2009       Cameroon       Cross sec.   Outpatients                                        Adults     36.9yr [\*](#TFN1){ref-type="other"}   208

  Magoue 2013                          2013                                   2010       Cameroon       Cross sec.   Outpatients                                        Adults     NR                                     232

  Outpatients                          Children                               NR         147                                                                                                                              

  Djuikoue 2016                        2016                                   2011--12   Cameroon       Cross sec.   Special population (outpatient women with\         Adults     NR                                     86
                                                                                                                     susp. UTI)                                                                                           

  Wilmore 2017                         2017                                   2014--15   Zimbabwe       Cross sec.   Special population (outpatient, HIV infected,\     Children   11yr                                   175
                                                                                                                     stable on ART)                                                                                       

  Herindrainy 2018                     2018                                   2015--16   Madagascar     Cross sec.   Special population (Pregnant women at\             Adults     26yr [\*](#TFN1){ref-type="other"}     275
                                                                                                                     delivery)                                                                                            

  Stanley 2018                         2018                                   2017       Uganda         Cross sec.   Special population (participants who reared\       both       21.7yr [\*](#TFN1){ref-type="other"}   300
                                                                                                                     animals, attending health facility with a fever\                                                     
                                                                                                                     and/or diarrhoea but without malaria)                                                                

  **ON HOSPITAL ADMISSION**                                                                                                                                                                                               

  Andriatahina 2010                    2010                                   2008       Madagascar     Cohort       On hospital admission                              Children   38.3m                                  244

  Kurz 2016                            2016                                   2014       Rwanda         Cohort       On hospital admission                              both       29yr                                   753

  Magwenzi 2017                        2017                                   2015       Zimbabwe       Cohort       On hospital admission                              Children   1.0yr                                  164

  Founou 2018                          2018                                   2017       South Africa   Cohort       On hospital admission                              Adults     NR                                     43

  Moremi 2018                          2018                                   2014--15   Tanzania       Cohort       On hospital admission                              Adults     NR                                     930

  Woerther 2011                        2011                                   2007--08   Niger          Cohort       Special population (Children with SAM)             Children   16.3m [\*](#TFN1){ref-type="other"}    55

  Isendahl 2012                        2012                                   2010       Guinea-\       Cross sec.   Special population (Children att. hospital w/\     Children   NR                                     408
                                                                                         Bissau                      fever or tachycardia)                                                                                

  Nelson 2014                          2014                                   2013       Tanzania       Cohort       Special population (Pregnant women and\            Neonate    0d                                     126
                                                                                                                     neonates, inpatient)                                                                                 

  Adults                               26.5yr [\*](#TFN1){ref-type="other"}   113                                                                                                                                         

  **INPATIENTS**                                                                                                                                                                                                          

  Lonchel 2013                         2013                                   2009       Cameroon       Cross sec.   Inpatients                                         Adults     46.8yr [\*](#TFN1){ref-type="other"}   121

  Magoue 2013                          2013                                   2010       Cameroon       Cross sec.   Inpatients                                         Adults     NR                                     208

  Schaumburg\                          2013                                   2010--11   Gabon          Cross sec.   Inpatients                                         Children   NR                                     200
  2013                                                                                                                                                                                                                    

  Desta 2016                           2016                                   2012       Ethiopia       Cross sec.   Inpatients                                         Adults     35yr                                   154

  Inpatients                           Children                               7yr        94                                                                                                                               

  Inpatients                           Neonate                                9d         19                                                                                                                               

  Tellevik 2016                        2016                                   2010--11   Tanzania       Cross sec.   Inpatients                                         Children   NR                                     353

  Nikema\                              2018                                   2015--16   Togo           Cross sec.   Special population (\<5yr with febrile\            Children   NR                                     81
  Pessinaba 2018                                                                                                     gastroenteritis)                                                                                     

  Marando 2018                         2018                                   2016       Tanzania       Cross sec.   Special population (Neonates with sepsis)          Neonate    6d                                     304

  **OTHER**                                                                                                                                                                                                               

  Tande 2009                           2009                                   2003       Mali           Cross sec.   Orphanage children                                 Children   NR                                     38

  Orphanage staff                      Adults                                 NR         30                                                                                                                               

  Magoue 2013                          2013                                   2010       Cameroon       Cross sec.   Hospital workers and their families                Adults     NR                                     87

  Relatives and carers of inpatients   Adults                                 NR         63                                                                                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Details of microbiologic testing procedures.

NR = not reported; API = analytical profile index; MALDI-TOF = Matrix-Assisted Laser Desorption/Ionization-Time of Flight.

  -------------------------------------------------------------------------------------------------------------------
  Study               Sample type   Screening method                              Speciation\   ESBL confirmation\
                                                                                  method        method
  ------------------- ------------- --------------------------------------------- ------------- ---------------------
  Ruppe 2009          Stool         Drigalski and chromagar                       NR            Double disc

  Tande 2009          Stool         Drigalski with cephalosporin                  API           Double disc

  Andriatahina 2010   Rectal Swab   Drigalski with cephalosporin                  API           Double disc

  Herindrainy 2011    Stool         Drigalski with cephalosporin                  API           Double disc

  Woerther 2011       Stool         Chromagar                                     API           PCR

  Albrechtova 2012    Rectal Swab   Mackonkey with cephalosporin                  API           Double disc

  Isendahl 2012       Rectal Swab   Chromagar                                     Vitek         Vitek

  Lonchel 2012        Stool         Mackonkey or Drigalski and cephalosporin      MALDI-TOF     Double disc

  Lonchel 2013        Stool         Mackonkey or Drigalski and cephalosporin      MALDI-TOF     Double disc

  Magoue 2013         Stool         Mackonkey or Drigalski and cephalosporin      NR            Double disc

  Schaumburg 2013     Rectal Swab   Chromagar                                     Vitek         Double disc

  Nelson 2014         Rectal Swab   Mackonkey with cephalosporin                  Biochemical   Double disc

  Chereau 2015        Stool         Drigalski with cephalosporin                  API           Double disc

  Desta 2016          Stool         Chromagar                                     Vitek         Vitek

  Djuikoue 2016       Stool         Drigalski with cephalosporin                  MALDI-TOF     Double disc

  Farra 2016          Stool         Chromagar                                     NR            Double disc

  Kurz 2016           Rectal Swab   Chromagar                                     API           Combination disc

  Mshana 2016         Stool         Mackonkey with cephalosporin                  API           Chromagar and vitek

  Ribeiro 2016        Stool         Chromagar                                     MALDI-TOF     PCR

  Tellevik, 2016      Stool         Chromagar                                     MALDI-TOF     Combination disc

  Magwenzi 2017       Stool or\     Chromagar and Mackonkey with cephalosporin\   API           Double disc
                      Rectal Swab   and nutrient broth with cephalosporin                       

  Moremi 2017         Stool         Mackonkey with cephalosporin                  Biochemical   Double disc

  Wilmore 2017        Stool         CLEDwith cephalosproin                        API and\      Combination disc
                                                                                  MALDI         

  Chirindze 2018      Stool         Mackonkey with cephalosporin                  API           Double disc

  Founou 2018         Rectal Swab   Mackonkey with cephalosporin                  API           Combination disc

  Herindrainy 2018    Stool or\     Chromagar                                     MALDI-TOF     Double disc
                      Rectal Swab                                                               

  Katakweba 2018      Stool         Mackonkey with cephalosporin                  MALDI-TOF     Double disc

  Marando 2018        Rectal swab   Mackonkey with cephalosporin                  Biochemical   Double disc

  Moremi 2018         Rectal swab   Mackonkey with cephalosporin                  vitek         vitek

  Nikema Pessinaba\   Stool         Drigalski with cephalosporin                  NR            NR
  2018                                                                                          

  Sanneh 2018         Stool         Drigalski And Cephalosporin                   NR            Double disc

  Stanley 2018        Stool         AST                                           BD phoenix    BD phoenix
  -------------------------------------------------------------------------------------------------------------------

The results of the risk of bias assessment are shown in [Figure 2](#f2){ref-type="fig"}. The most notable potential for biased ESBL-E prevalence estimates resulted from selection of study populations. Several studies recruited a selected group, which we defined as a special population: pregnant women, street children, children and staff of an orphanage, or food handlers in schools. These are likely to produce a biased estimate of community prevalence. Though microbiological culture methods were frequently described in a reproducible manner, few studies reported quality control procedures, resulting in an assessment of moderate risk of bias for the majority of studies across this domain.

![Results of risk of bias assessment.\
Domain 1: Are the characteristics of the participants included in the study adequately described? Domain 2: Are the eligibility criteria to enter the study explicit and appropriate? Domain 3: Were stool culture results precise and reported? Domain 4: Were the methods of extended-spectrum beta-lactamase (ESBL) confirmatory testing precise?](wellcomeopenres-4-17211-g0001){#f2}

Overall ESBL-E colonisation prevalence was extremely heterogeneous across studies ranging from 5--84% (median 31%) with no trend by year of publication ( [Figure 3](#f3){ref-type="fig"}). Some heterogeneity was explained by location of sampling ( [Figure 4](#f4){ref-type="fig"}): inpatients tended to have the highest colonisation prevalence with community members the least. There was no clear difference in prevalence between neonates, children or adults ( [Figure 5](#f5){ref-type="fig"}). Pooled random-effect summary estimates were therefore calculated for differing location of sampling: community members (18% \[95% CI 11--28%\]), outpatients (23% \[95% CI 13-39%\]), inpatients on hospital admission (32% \[95% CI 24--41%\]) and inpatients (55% \[95% CI 49-60%\]), though in each stratum significant heterogeneity remained (I ^2^ 76--97%) so these summary estimates should be treated with caution ( [Figure 4](#f4){ref-type="fig"}).

![Overall extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) colonization prevalence by study.](wellcomeopenres-4-17211-g0002){#f3}

![Extended-spectrum beta-lactamase (ESBL) colonisation by study with pooled random effect summary estimates stratified by location of sampling.\
ESBL prop. = proportion of ESBL producing Enterobacteriaceae.](wellcomeopenres-4-17211-g0003){#f4}

![Extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) carriage prevalence stratified by age group.](wellcomeopenres-4-17211-g0004){#f5}

Two-thirds (21/32) of studies performed an analysis to identify factors associated with ESBL-E colonisation ( [Table 4](#T4){ref-type="table"}). Prior hospitalisation was assessed as a risk factor in 13 studies, and a statistically significant association found in 4/13, with odds ratios of 2.1-8.5. Antimicrobial exposure was assessed in 13 studies, and a statistically significant association found in 5/13 with odds ratios of 1.6-27.0. Using water from a borehole ^[@ref-28]^, boiling water before drinking ^[@ref-14]^ and having private inside access to drinking water ^[@ref-10]^ were found to be associated with a lower prevalence of ESBL-E colonisation in three different studies. One study found that a higher socio-economic status was associated with a lower ESBL-E prevalence ^[@ref-29]^, and one the opposite ^[@ref-13]^. Only two studies addressed the association between HIV status and ESBL-E colonisation status; one, in adults found no association ^[@ref-9]^, whereas the other, in children, found a strong association ^[@ref-17]^. Only one study assessed the association between animals in the home as ESBL-E colonisation ^[@ref-10]^, finding no association.

###### Assessed and significant risk factors in the included studies.

mv = multivariate, uv = univariate, HH = household, abx = antibiotics, SES = socio-economic status, HC = health centre, ART = antiretroviral therapy, VL = viral load, PROM = premature rupture of membranes, WASH = water, sanitation and hygiene. UTI = urinary tract infection, NR = not reported. \* confidence interval crosses 1; original publication used fisher's exact test and found p \< 0.05.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                           Risk factors assessed                                 Analysis   Significant risk factors               Odds ratio (95%\
                                                                                                                                                          CI)
  ----------------------------------------------- ----------------------------------------------------- ---------- -------------------------------------- ------------------------------------------------
  Tande 2009                                      Adults with direct contact with the children in\      uv         Contact with orphanage children        19.7 (3.2 - 201.3)
                                                  orphanage                                                                                               

  Andriatahina\                                   Age, gender, patient origin (home vs health\          mv         Hospitalisation last 30d               7.4 (2.9-18.3)
  2010                                            facility), abx or hospitalisation last 30days,\                                                         
                                                  admitting dx, infection on admission                                                                    

  Herindrainy 2011                                SES, no. of rooms occupied, ratio occupants:\         mv         Occupation HH head unemployed\         9.1 (1.6-53.9)
                                                  room                                                             vs manager                             

  Isendahl 2012                                   Age, gender, weight, MUAC, breastfeeding,\            uv         Bedsharing                             1.9 (1.0 - 3.4)
                                                  bedsharing, children in HH, abx, hospitalisation                                                        

  Lonchel 2013                                    Age, gender, hospital, diagnosis, abx within\         mv         Hospitalisation during the previous\   4.13 (1.37--12.78)
                                                  3m, hospitalisation within 1yr                                   year                                   

  Admission with infection                        0.30 (0.10--0.82)                                                                                       

  Intermediate vs tertiary hospital               4.10 (1.77--9.59)                                                                                       

  Schaumburg\                                     Age, hospitalisation, residence, sex, diagnosis,\     mv         Age \<=5                               2.2 (1.1--4.8)
  2013                                            abx use                                                                                                 

  Hospitalization 5--7 days vs \< 5               5.1 (1.6--18.4)                                                                                         

  Hospitalization for =7 days vs \< 5             30.6 (5.8--566.0)                                                                                       

  Hospital stay during the past\                  2.1 (1.1--4.0)                                                                                          
  12 months                                                                                                                                               

  Nelson 2014                                     For neonates: Gestation, birthweight, gender,\        uv         Antibiotic use                         10.8 (0.6 - 186) [\*](#TFN2){ref-type="other"}
                                                  delivery method, ward, abx use                                                                          

  For mothers: Delivery mode, admission within\   Nothing                                                                                                 
  30d, abx within 3m, abx within 30d, current\                                                                                                            
  abx, catheter, HIV status                                                                                                                               

  Chereau 2015                                    Study area, age, education, marital status,\          mv         Private inside access to drinking\     0.3 (0.1--0.8)
                                                  type house, electricity, type of birth attendant,\               water                                  
                                                  toilets, water, animals at home, hospitalisation,\                                                      
                                                  abx use                                                                                                 

  Desta 2016                                      Higher maximum bed capacity per room,\                uv         Sharing room vs not                    4.0 (2.3 to 5.3)
                                                  increasing number of patients admitted in\                                                              
                                                  single room                                                                                             

  Djuikoue 2016                                   Age, pregnancy, abx last 3m, hospital last 3m         uv         None                                   

  Farra 2016                                      Age, gender, comorbidity, SES, nutritional\           mv         Highest SES class vs lowest            31.06 (2.49--387.13)
                                                  status, animals at home, toilets, urban/rural, hh\                                                      
                                                  members, meals                                                                                          

  Kurz 2016                                       Age, gender , residence, ward, referral, other\       mv         ESBL colonised caregiver,              2.88 (1.80-4.61)
                                                  healthcare 3m, abx 3m, education, SES, water\                                                           
                                                  source, food, time to HC, caregiver ESBL\                                                               
                                                  status                                                                                                  

  Antibiotics within 3 months,                    2.70 (1.59-4.58)                                                                                        

  Frequently consume eggs                         6.52 (1.75-24.31)                                                                                       

  Boil water prior to drinking                    0.59 (0.37-0.92)                                                                                        

  Mshana 2016                                     Age, region, no of children in house, abx use\        mv         Older age (per yr),                    1.07 (1.04--1.10)
                                                  within 1m, admission within 1yr                                                                         

  Hospital admission last yr                      7.4 (1.43--38.5)                                                                                        

  Abx last 3m                                     27 (6.63--116),                                                                                         

  Tellevik, 2016                                  Age, gender, residence, parental education,\          mv         HIV vs no HIV,                         9.99 (2.52--39.57),
                                                  child group, nutritional status, use of abx within\                                                     
                                                  14 days                                                                                                 

  Kinondoni district,                             2.62 (1.49--4.60)                                                                                       

  Abx last 14d                                    1.61 (1.07--2.41)                                                                                       

  Moremi 2017                                     Age, education, herb use, source of income,\          mv         Local herb use,                        3.3 (1.31--8.31),
                                                  source of food, street child type                                                                       

  Sleep on streets vs not                         2.8 (1.04--7.65)                                                                                        

  Wilmore 2017                                    Age, gender, CD4, VL, ART duration, admitted\         mv         ART \<1yr                              8.47 (2.22--2.27)
                                                  to hospital with pneumonia in last 12m, adm to\                                                         
                                                  hospital in at 12 m                                                                                     

  Admission with pneumonia in last\               8.47 (1.12--64.07)                                                                                      
  12m                                                                                                                                                     

  Marando 2018                                    Age, gender, weight, admission where, clinical\       mv         Current abx use                        1.73 (1.00-2.97),
                                                  factors, abx use, PROM                                                                                  

  ESBL colonised mother                           2.19 (1.26-3.79)                                                                                        

  Moremi 2018                                     Age, gender, history of antibiotic use, history of\   mv         Older age (per year)                   1.01 (1.00--1.02)
                                                  admission, history of surgery                                                                           

  Nikema\                                         Age, gender, site, drinking water source, time\       mv         Drink non borehole water vs\           3.47 (1.22-9.82)
  Pessinaba 2018                                  to sample analysis                                               borehole                               

  Sanneh 2018                                     WASH behaviours, hospitalised within 3m,\             uv         Lack of food handling training and\    NR
                                                  invasive procedures, abx within 3m, abx from\                    knowledge of the principle of food\    
                                                  street, completing abx, diarrhoea/UTI 3m, food\                  safety                                 
                                                  handling training                                                                                       

  Abx within 3m                                   NR                                                                                                      

  Stanley\                                        Age, gender, health facility, presentation            uv         none                                   
  2018                                                                                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Of the 6 cohort studies, all sampled participants on admission to hospital and on discharge, a median 5.6-8 days later, and all found an increase in ESBL-E colonisation prevalence between the two sampling points ( [Table 5](#T5){ref-type="table"}). No study longitudinally sampled ESBL colonisation in the community, either in community dwellers or in those discharged from hospital.

###### Longitudinal ESBL prevalence in included cohort studies.

NR = not reported. \* = median not given but admission length was 2--10 days.

  Study               Study population      ESBL prevalence   Median follow up   
  ------------------- --------------------- ----------------- ------------------ ----------------------------------
  Andriatahina 2010   Children              51/244 (21%)      88/154 (57%)       5.7d
  Woerther 2011       Children              17/55 (31%)       15/16 (94%)        8d
  Nelson 2014         Neonates              32/126 (25%)      77/126 (61%)       7d
  Kurz 2016           Adults and children   195/392 (50%)     173/208 (83%)      6d
  Magwenzi 2017       Children              86/164 (52%)      115/164 (70%)      5.6d
  Moremi 2018         Adults                220/930 (24%)     143/272 (53%)      NR [\*](#TFN5){ref-type="other"}

Discussion
==========

ESBL-E colonisation is common across sSA, though with significant unexplained heterogeneity between study locations and populations. Community ESBL-E colonisation ranges from 5% in adults in Gambia in 2015 to 59% in children in the Central African Republic in 2013, the latter comparable to the highest described colonisation prevalence in the world ^[@ref-5]^. Our pooled estimate suggests 18% (95% CI 11--29%) of people in sSA are colonised with ESBL-E, a higher prevalence than in high income settings. In Europe, community prevalence of ESBL-E colonisation is reported to range from 3.7% in Spain in 2004 to 7.3% in the UK in 2014 ^[@ref-38]--\ [@ref-41]^, similar to the United States where a community prevalence of 3.4% was reported in healthy children ^[@ref-42]^. In many of the estimates of studies included in this review, the reported prevalence of ESBL-E is more comparable to that reported in Asia (46% \[95% CI 29--63%\] ^[@ref-5]^).

The profound differences in community ESBL-E colonisation prevalence between sSA and high-resource settings warrants further investigation, beyond the assessment of risk factors we have identified in this review. Hospitalisation and antimicrobial use are likely drivers of colonisation in the studies, with higher prevalence seen in hospitalised individuals and prior hospitalisation and antimicrobial exposure frequently identified as risk factors for colonisation. Obversely and consistent with a putative faecal-oral transmission route, use of borehole water, a private indoor water source and boiling water before drinking were associated with reduced ESBL-E colonisation risk, and it may be that poor water, sanitation and hygiene (WASH) infrastructure and practices in sSA are driving high ESBL-E colonisation prevalence. This speaks to a role for poverty in driving ESBL-E colonisation; however, this is likely complex, and context-dependant, as evidenced by conflicting findings of the effect of socio-economic status on colonisation from two studies in different settings.

More broadly, this review highlights areas where data that could inform interventions to interrupt ESBL-E transmission are lacking. In the community, long-term longitudinal ESBL-E colonisation studies are necessary to understand the dynamics of community ESBL-E transmission, particularly the role of within household transmission, and the role of household animals. In health facilities, the determinants of apparent ESBL-E acquisition need to be clearly identified to design pragmatic intervention studies in the context of limited resources. Surprisingly, the role of HIV in driving the high ESBL-E colonisation prevalence in sSA is unknown. HIV is known to profoundly affect gut function, but we identified only two studies which have assessed HIV status as a risk factor for ESBL-E colonisation.

There are limitations of our review. Our search strategy may have missed studies that would otherwise be included. However, using broader inclusion criteria than a recent review of worldwide ESBL-E community colonisation prevalence ^[@ref-5]^, we have identified many more studies from sSA. Risk of bias assessment in observational studies is difficult, with no gold standard, and the tool we have used may misclassify studies with regard to bias. Significant heterogeneity remaining despite stratification warrants caution in interpreting summary estimates. The number of identified studies and participants are small compared to the population of sSA and several countries are over-represented, meaning that care should be taken in generalising these findings across the diverse settings of sSA. Some potentially important risk factors for ESBL-E colonisation (HIV infection and livestock exposure, for example) are not explored in the studies we have identified, and their role in driving colonisation remains unclear.

In conclusion, ESBL-E colonisation in sSA is common, and in places comparable to the highest prevalence in the world, though with significant unexplained heterogeneity between countries and populations. Hospitalisation, antimicrobial use, and poor WASH infrastructure and practices may be contributing to high prevalence; the roles of HIV and animal-human transmission remain unknown. Given the threat to human health of ESBL-E, data to fully characterise routes and drivers of transmission in sSA are necessary to design interventions to interrupt transmission in this setting.

Data availability
=================

Underlying data
---------------

All data underlying the results are available as part of the article and no additional source data are required.

Extended data
-------------

Zenodo: Risk of bias tool and PRISMA checklist used for the publication: Gut mucosal colonisation with extended-spectrum beta-lactamase producing Enterobacteriaceae in sub-Saharan Africa: a systematic review and meta-analysis, <http://doi.org/10.5281/zenodo.3478278> ^[@ref-43]^

This project contains the following extended data:

1.  Risk of bias tool used in the study

Reporting guidelines
--------------------

Zenodo: PRISMA checklist for: Gut mucosal colonisation with extended-spectrum beta-lactamase producing Enterobacteriaceae in sub-Saharan Africa: a systematic review and meta-analysis, <http://doi.org/10.5281/zenodo.3478278> ^[@ref-43]^.

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/legalcode) (CC-BY 4.0).
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Among the targets of the AntiMicrobial Resistance, ESBL-producing Enterobacteriaceae are a real worldwide issue not well-studied in Africa. The previous review of Storberg (2014 ^[@rep-ref-37453-1]^) showed ESBL-producing Enterobacteriaceae are a large problem in African healthcare institutions and communities. However, this author highlighted the scarcity of African data about this topic. This new review shows the same trend with only 32 considered studies from 19 countries and among them 15 studies from 3 countries (Tanzania, Madagascar, and Cameroon).

\"Inclusion criteria were any prospective cross-sectional or cohort study that had screened for gut mucosal colonization of ESBL-E in any population in sSA for which it was possible to extract a numerator and denominator to calculate an ESBL-E colonization prevalence.\" Is that enough to explain that only 32 studies to 2975 were included? These results ask about other countries\' lab capacities and about the quality of some works: 2975 identified and 32 included. Does that mean 2943 studies were laboratory-based studies?

However, the methodology seems to be strong. The risk of bias was included and figure 2 a good way to assess the studies. Could we imagine from this review some proposals for better-implementing studies about this topic, leading to facilitating comparison between countries?

About prevalence and risk factors the authors seem to be surprised by differences between countries but it is a picture of the high diversity of the Africa region. Once, higher socio-economic status will be a protector because of sanitation and in another country this status will be a risk factor because the load of antimicrobial exposure will be more serious. 

Because of the design of the studies included in this review, the livestock transmission is not evocated as one of the such risk factors. In discussion, the authors should have to point to the lack of studies concerning assessment of risk from livestock.

Undoubtedly, the most relevant intervention to reduce the carriage of ESBL-E will be the systematic implementation of WASH infrastructures. However, this kind of intervention will need to be assessed for convincing decision-makers to involve themselves in this strategy.
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We thank the reviewer for their review, and agree that systematic WaSH interventions are likely crucial for tackling antimicrobial resistance in sSA.

2943 studies were excluded at the abstract review stage, largely because they were not relevant to the subject of the review (i.e. were not concerned with ESBL-E carriage at all); others did not take place in sSA, or were review articles, case reports, or studies looking at invasive ESBL-E infection. Unfortunately we did not capture the reasons for rejection for each abstract.

We agree that risk factors for ESBL-E carriage are likely to be context dependent across the diverse settings of sSA. We also agree that there are a number of risk factors (including livestock) that are not explored as potential drivers of ESBL-E carriage in the available studies, and hence their role is not clear. We have amended the limitations section to highlight this.

10.21956/wellcomeopenres.16981.r36859

Reviewer response for version 1

Kariuki

Samuel

1

Referee

https://orcid.org/0000-0003-3209-9503

Centre for Microbiology Research, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya

**Competing interests:**No competing interests were disclosed.

6

11

2019

Copyright: © 2019 Kariuki S

2019

This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Version 1

Extended spectrum beta-lactamase (ESBL) producing enteric pathogens are a major cause of hospitalization and mortality in sub-Saharan Africa (SSA), more so because alternative options for effective treatment of infections are either too expensive to afford or are completely unavailable in these settings. I believe this review is timely as it provides information on the extent to which data from the region could provide insight into the extent of gut mucosal colonization (a precursor for invasive disease when immune-suppression may happen) and ensure that we institute policies that effectively reduce colonization and control of infections in these settings. 

The authors observed a rather disturbing trend in data spread across the continent as only a meager 32 studies could qualify to have had data on gut colonization and ESBL testing done. Indeed only 6 of these studies followed up patients beyond the hospital discharge. The authors observed that antimicrobial use was associated with increased risk of ESBL-E colonization, and protected water sources or water treatment by boiling may reduce risk in affected patients.

The authors did their best to review all available data to answer their key review questions. The methodology was robust and systematic, and the analysis is complex but easy to follow. The major weakness in this review (which is really non-methodological) is the small number of studies available for the large population of SSA and for which major conclusions to be drawn from such a small sample size would be greatly flawed. There is no doubt that gut mucosal colonization with ESBL-producing gut pathogens plays a major role as a risk factor for invasive disease in hospitalized patients, this has been shown in studies in other parts of the world and such evidence is therefore crucial to compare with SSA. The poor implementation of WaSH in communities and Infection Prevention and control (IPC) strategies in healthcare settings certainly add to the challenges associated with prevention of gut-associated mucosal colonization with ESBL-producing bacteria. It is crucial that the authors clearly indicate the major flaw with the conclusion especially as it is based on a rather small and thinly spread number of studies in SSA. Although HIV and the role of livestock transmission of these zoonotic pathogens in studies in SSA was inconclusive, the fact that the studies reviewed may not necessarily have had these as study objectives cannot be ruled out. Interpretation of such review data should be therefore done with caution especially pertaining to possible key risk factors in disease transmission and gut colonization.
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We thank the reviewer for their review, and agree that the available data are scanty and it is not at all clear that the findings are generalisable across the diverse countries of sub-Saharan Africa, especially as some countries are over-represented in the dataset. We have amended the limitations section of our manuscript to highlight the lack of data and, in particular, that the role of animal to human transmission and HIV infection play in driving ESBL-E colonisation in sSA is unclear.
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